Investors Overview

Webcast ImageWebcast
Q3 2014 Bacterin International Holdings Inc Earnings Conference Call (Live)
11/06/14 at 10:00 a.m. ET
Q3 2014 Bacterin International Holdings Inc Earnings Conference Call
Thursday, November 6, 2014 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Bacterin International Holdings, Inc., Belgrade, MT (NYSE: BONE), a developer of bioactive coatings for medical applications and revolutionary bone graft material, processes and markets innovative, biologic allografts for transplantation. The Company’s biologic scaffolds, OsteoSponge®, OsteoSponge® SC and OsteoWrap®, are made from demineralized bone that is malleable and flexible, which enables more efficient and precise handling. It also markets BacFast® and OsteoLock®, which are used in ...
More

Stock Quote
BONE (Common Stock)
ExchangeNYSE (US Dollar)
Price$4.16
Change (%) Stock is Down 0.02 (0.48%)
Volume2,045
Data as of 10/31/14 3:59 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock Chart
Stock chart for: 03NA000000BONE
Recent News
DateTitle 
10/29/14Photo Release -- Bacterin Announces New Demineralized Bone Matrix Constructs for Spine Applications
BELGRADE, Mont., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of bone graft material and coatings for medical applications, today announced the release of two unique new products for use in spinal procedures, 3Demin™ Boats and 3Demin™ Strips. These products complement Bacterin's existing bone graft portfolio as our new technology allows us to provide larger constructs suitable for multi-level spinal fusion procedures. ... 
Printer Friendly Version
10/27/14Bacterin Awarded Grant From the Montana Board of Research and Commercialization Technology
BELGRADE, Mont., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of bone graft material and coatings for medical applications, has been awarded a grant from the Montana Board of Research and Commercialization Technology (MBRCT) in the amount of $192,484 for the development and commercialization of a novel regenerative medicine technology. The MBRCT states that, "The purpose of the program is to encourage economic developmen... 
Printer Friendly Version
10/23/14Bacterin to Report Third Quarter 2014 Financial Results on November 5, 2014
BELGRADE, Mont., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced that it will release its financial results for the period ended September 30, 2014, on November 5, 2014 at the close of the financial markets. An accompanying conference call hosted by Dan Goldberger, Chief Executive Officer and John Gandolfo, Chief Financial Officer, t... 
Printer Friendly Version
10/22/14Bacterin Presents Preclinical Results of an Efficacious Antimicrobial Orthopedic Device Coating
BELGRADE, Mont., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of bone graft material and coatings for medical applications, presented preclinical results of a robust and efficacious antimicrobial coating for orthopedic hardware at the 2014 Orthopaedic Trauma Association (OTA) Annual Meeting. The coating is intended to address one of the most serious complications in orthopedic surgery, implant-associated infections. Of t... 
Printer Friendly Version
More

Upcoming Events
DateTitle
11/06/14 10:00 a.m. ET
Q3 2014 Bacterin International Holdings Inc Earnings Conference Call
More

Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Bacterin International Holdings Inc posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.